ICON Public (NASDAQ:ICLR) Upgraded at StockNews.com

ICON Public (NASDAQ:ICLR) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

ICLR has been the topic of several other research reports. TD Cowen raised their price objective on shares of ICON Public from $349.00 to $373.00 and gave the company a “buy” rating in a research report on Friday, May 31st. Truist Financial reaffirmed a “buy” rating and issued a $383.00 price objective on shares of ICON Public in a research note on Wednesday. Barclays lowered their target price on shares of ICON Public from $355.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. The Goldman Sachs Group started coverage on ICON Public in a research report on Thursday, June 6th. They issued a “buy” rating and a $370.00 price target for the company. Finally, William Blair reissued an “outperform” rating on shares of ICON Public in a report on Friday, May 31st. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $351.67.

ICON Public Stock Up 3.3 %

ICLR traded up $9.33 on Wednesday, reaching $289.81. 1,403,151 shares of the company traded hands, compared to its average volume of 561,710. ICON Public has a 52-week low of $221.20 and a 52-week high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The company has a market cap of $23.91 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 1.35 and a beta of 1.22. The stock’s 50 day moving average price is $320.77 and its 200-day moving average price is $319.36.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the prior year, the business posted $2.96 earnings per share. ICON Public’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, sell-side analysts expect that ICON Public will post 14.54 EPS for the current fiscal year.

Institutional Trading of ICON Public

A number of hedge funds have recently bought and sold shares of ICLR. GAMMA Investing LLC raised its position in shares of ICON Public by 22.5% during the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock valued at $58,000 after buying an additional 32 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after acquiring an additional 42 shares during the period. Motco grew its holdings in shares of ICON Public by 1.5% during the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after purchasing an additional 59 shares in the last quarter. First National Bank of Hutchinson increased its position in shares of ICON Public by 5.7% during the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after purchasing an additional 61 shares during the period. Finally, Riverview Trust Co acquired a new position in shares of ICON Public in the first quarter valued at $31,000. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.